StockData

Aclaris Therapeutics vs Rani Therapeutics

ACRS and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACRS and RANI compare

Aclaris Therapeutics is the larger company, worth 7.0 times as much as Rani Therapeutics ($531M against $75.3M).

Rani Therapeutics grew revenue faster over the last twelve months (306% versus −51.0% for Aclaris Therapeutics).

Rani Therapeutics keeps more of each dollar of sales as profit, with a net margin of −618% compared with −921% at Aclaris Therapeutics.

Aclaris Therapeutics scores higher on the StockData Score (5 against 3 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACRSRANI
Size and price
Market cap$531M$75.3M
Share price$3.60$0.540
Change, 1 year55.4%−72.0%
Change, 5 years−71.4%−98.2%
Beta (5Y)0.961.60
Employees7369
StockData Score
Total score5 (better)3
Valuation score01 (better)
Growth score01 (better)
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S64.6×15.4× (better)
P/B4.3×1.9× (better)
FCF yield−11.7% (better)−27.0%
Fair value$1.42$0.388
Margin of safety−155%−39.1% (better)
Growth
Revenue growth (TTM)−51.0%306% (better)
Revenue growth, 5Y average3.8%28.7% (better)
Profitability
Gross margin79.5%–
Operating margin−1050%−676% (better)
Net margin−921%−618% (better)
FCF margin−757%−417% (better)
Return on equity−59.1% (better)−179%
Return on invested capital–−145%
Financial health
Debt / equity0.00–
Interest coverage–−28.2×
Current ratio3.465.31 (better)
Altman Z-score−3.16−0.67 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.3%32.7%
Held by insiders13.3%30.6%
Insider net buying, 12 months−$1.4M$49.7K (better)
Short interest, % of float9.1%8.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.